Top

Supportive Care in Cancer

Published in:

01-10-2008 | Review

Metastatic bone pain: treatment options with an emphasis on bisphosphonates

Authors: Roger von Moos, Florian Strasser, Silke Gillessen, Kathrin Zaugg

Published in: Supportive Care in Cancer | Issue 10/2008

Abstract

Introduction

One of the key targets for metastatic cancer cells is the skeleton. Once metastatic cells are established within the bone matrix, skeletal integrity becomes increasingly compromised. Bone lesions lead to various complications, including bone pain, fractures and spinal cord compression.

Mechanisms of bone pain

Bone pain is debilitating and affects quality of life of the patient. In addition, it increases the use of health care resources. Many patients with metastatic bone disease experience substantial bone pain despite state-of-the-art systemic analgesic treatment. Incident pain is the predominant pain syndrome.

Treatment options for bone pain

Typically, this syndrome requires moderate baseline analgesia with increased on-demand doses. Other techniques for treating bone pain, including radiation therapy, neuraxial application of analgesics, nerve blocks and local stabilisation procedures, should be considered. In addition, therapy with bisphosphonates targeting bone-specific pain is an important strategy. This review discusses the various management options for bone pain arising from metastatic bone disease.

Anselmetti GC, Corgnier A, Debernardi F, Regge D (2005) Treatment of painful compression vertebral fractures with vertebroplasty: results and complications. Radiol Med (Torino) 110(3):262–272

Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D (2003) Short-term, high-dose pamidronate induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41(5):E18 doi:10.1016/S0272-6386(03)00373-1 PubMedCrossRef

Bates T (1992) A review of local radiotherapy in the treatment of bone metastases and cord compression. Int J Radiat Oncol Biol Phys 23(1):217–221PubMed

Berenson JR, Lichenstein A, Porter L, Dimopoulos MA, Bordoni R, George S et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334(8):488–493 doi:10.1056/NEJM199602223340802 PubMedCrossRef

Body JJ (1999) Bisphosphonates for metastatic bone pain. Support Care Cancer 7(1):1–3 doi:10.1007/s005200050213 PubMedCrossRef

Body JJ (2001) Bisphosphonates in the treatment of metastatic breast cancer. J Mammary Gland Biol Neoplasia 6(4):477–485 doi:10.1023/A:1014795216669 PubMedCrossRef

Body JJ, Mancini I (2002) Bisphosphonates for cancer patients: why, how and when? Support Care Cancer 10(5):399–407 doi:10.1007/s005200100292 PubMedCrossRef

Body JJ, Diel IJ, Bell R, Pecherstorfer M, Lichinitser MR, Lazarev AF et al (2004) Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain 111(3):306–312 doi:10.1016/j.pain.2004.07.011 PubMedCrossRef

Body JJ, Pfister T, Bauss F (2005) Preclinical perspectives on bisphosphonate renal safety. Oncologist 10(suppl 1):3–7 doi:10.1634/theoncologist.10-90001-3 PubMedCrossRef

10.

Chang JT, Green L, Beitz J (2003) Renal failure with the use of zoledronic acid. N Engl J Med 349(17):1676–1679 doi:10.1056/NEJM200310233491721 PubMedCrossRef

11.

Cheung G, Chow E, Holden L, Vidmar M, Danjoux C, Yee AJ et al (2006) Percutaneous vertebroplasty in patients with intractable pain from osteoporotic or metastatic fractures: a prospective study using quality-of-life assessment. Can Assoc Radiol J 57(1):13–21PubMed

12.

Cleeland CS, Janjan NA, Scott CB, Seiferheld WF, Curran WJ (2000) Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. Int J Radiat Oncol Biol Phys 47(1):203–208 doi:10.1016/S0360-3016(99)00276-X PubMed

13.

Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY et al (2006) Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24(30):4895–4900 doi:10.1200/JCO.2006.05.9212 PubMedCrossRef

14.

Clemons M, Dranitsaris G, Ooi W, Cole DE (2008) A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Res Treat 108(1):79–85 doi:10.1007/s10549-007-9583-y PubMedCrossRef

15.

Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165–176 doi:10.1053/ctrv.2000.0210 PubMedCrossRef

16.

Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(suppl. 4):14–27 doi:10.1634/theoncologist.9-90004-14 PubMedCrossRef

17.

Coleman RE, Purohit OP, Vinholes JJ, Zekri J (1997) High dose pamidronate: clinical and biochemical effects in metastatic bone disease. Cancer 80(Suppl 8):1686–1690 doi:10.1002/(SICI)1097-0142(19971015)80:8+<1686::AID-CNCR20>3.0.CO;2-V PubMedCrossRef

18.

Dalton JA, Youngblood R (2000) Clinical application of the World Health Organization analgesic ladder. J Intraven Nurs 23(2):118–124PubMed

19.

Davis MP, Walsh D (2004) Epidemiology of cancer pain and factors influencing poor pain control. Am J Hospice Palliat Care 21(2):137–142 doi:10.1177/104990910402100213 CrossRef

20.

Davis MP, Walsh D, Lagman R, LeGrand SB (2005) Controversies in pharmacotherapy of pain management. Lancet Oncol 6(9):696–704 doi:10.1016/S1470-2045(05)70317-X PubMedCrossRef

21.

De Negri P, Tirri T, Paternoster G, Modano P (2007) Treatment of painful osteoporotic or traumatic vertebral compression fractures by percutaneous vertebral augmentation procedures: a nonrandomized comparison between vertebroplasty and kyphoplasty. Clin J Pain 23(5):425–430 doi:10.1097/AJP.0b013e31805593be PubMedCrossRef

22.

Diel IJ (2001) Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol 28(4):75–80 (suppl 11)doi:10.1053/sonc.2001.25429 PubMedCrossRef

23.

Diel IJ, Body JJ, Lichinitzer MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B, MF 4265 Study Group (2004) Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 40(11):1704–1712 doi:10.1016/j.ejca.2004.03.025 PubMedCrossRef

24.

Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA et al (2006) Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 91(7):968–971PubMed

25.

Eisenberg E, River Y, Shifrin A, Krivoy N (2007) Antiepileptic drugs in the treatment of neuropathic pain. Drugs 67(9):1265–1289 doi:10.2165/00003495-200767090-00003 PubMedCrossRef

26.

Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al (2003) Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 21(17):3335–3342PubMedCrossRef

27.

Fernandez-Tresguerres-Hernandez-Gil I, Alobera-Gracia MA, del-Canto-Pingarron M, Blanco-Jerez L (2006) Physiological bases of bone regeneration II. The remodeling process. Med Oral Patol Oral Cir Bucal 11:E151–E157PubMed

28.

Fulfaro F, Arcara C, Badalamenti G et al (2003) The use of zoledronic acid in the treatment of painful bone metastases from prostate cancer. J Clin Oncol 22(suppl):428 abstract 1721

29.

Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR et al (2005) The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17(5):555–559PubMed

30.

Goblirsch MJ, Zwolak PP, Clohisy DR (2006) Biology of bone cancer pain. Clin Cancer Res 12(Suppl 20):6231s–6235s doi:10.1158/1078-0432.CCR-06-0682 PubMedCrossRef

31.

Haddad P, Wong RK, Pond GR, Soban F, Williams D, McLean M et al (2005) Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastases: a 5-year review. Clin Oncol (R Coll Radiol) 17(6):430–434 doi:10.1016/j.clon.2005.03.012

32.

Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT (2004) Bone imaging in metastatic breast cancer. J Clin Oncol 22(14):2942–2953 doi:10.1200/JCO.2004.08.181 PubMedCrossRef

33.

Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd et al (2005) Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97(11):798–804PubMedCrossRef

34.

Harvey HA, Cream LR (2007) Biology of bone metastases: causes and consequences. Clin Breast Cancer 7(suppl 1):S7–S13PubMedCrossRef

35.

Healey JH, Shannon F, Boland P, DiResta GR (2003) PMMA to stabilize bone and deliver antineoplastic and antiresorptive agents. Clin Orthop Relat Res (415 suppl):S263–S275 doi:10.1097/01.blo.0000093053.96273.ee

36.

Heidenreich A, Hofmann R, Engelmann U (2001) The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol 165(1):136–140 doi:10.1097/00005392-200101000-00033 PubMedCrossRef

37.

Heidenreich A, Body J, Bergström B (2004) Relief from severe metastatic bone pain with intensive ibandronate dosing. Support Care Cancer 12:407 (A-127)

38.

Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, American Society of Clinical Oncology et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21(21):4042–4057 doi:10.1200/JCO.2003.08.017 PubMedCrossRef

39.

Hoskin PJ (2003) Bisphosphonates and radiation therapy for palliation of metastatic bone disease. Cancer Treat Rev 29(4):321–327 doi:10.1016/S0305-7372(03)00013-6 PubMedCrossRef

40.

Hurst M, Noble S (1999) Clodronate: a review of its use in breast cancer. Drugs Aging 15(2):143–166 doi:10.2165/00002512-199915020-00007 PubMedCrossRef

41.

Jagdev SP, Purohit OP, Heatley S, Herling C, Coleman RE (2001) Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. Ann Oncol 12(10):1433–1438 doi:10.1023/A:1012506426440 PubMedCrossRef

42.

Janjan N (2001) Bone metastases: approaches to management. Semin Oncol 28(4):28–34 (suppl 11) doi:10.1053/sonc.2001.25444 PubMedCrossRef

43.

Johnson G, Gralow J, Benson P (2004) Use of bisphosphonates for the palliative management of metastatic bone pain in the US. Support Care Cancer 12:400 (A-105)

44.

Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y et al (2005) Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314–3321 doi:10.1200/JCO.2005.05.116 PubMedCrossRef

45.

Kozlow W, Guise TA (2005) Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 10(2):169–180 doi:10.1007/s10911-005-5399-8 PubMedCrossRef

46.

Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT (1999) Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 246(1):67–74 doi:10.1046/j.1365-2796.1999.00507.x PubMedCrossRef

47.

Kuehn KD, Ege W, Gopp U (2005) Acrylic bone cements: mechanical and physical properties. Orthop Clin North Am 36(1):29–39 doi:10.1016/j.ocl.2004.06.011 PubMedCrossRef

48.

Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d’Othée BJ et al (2007) Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 25(22):3281–3287 doi:10.1200/JCO.2006.09.2940 PubMedCrossRef

49.

Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Common 28(8):623–630 doi:10.1097/MNM.0b013e32825a6adc CrossRef

50.

Lipton A (2003) Bisphosphonates and metastatic breast carcinoma. Cancer 97(suppl 3):848–853 doi:10.1002/cncr.11123 PubMedCrossRef

51.

Lipton A (2003) Bone metastases in breast cancer. Curr Treat Opt Oncol 4(2):151–158 doi:10.1007/s11864-003-0016-9 CrossRef

52.

Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88(5):1082–1090 doi:10.1002/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z PubMedCrossRef

53.

LoRusso P (2001) Analysis of skeletal-related events in breast cancer and response to therapy. Semin Oncol 28(4):22–27 (suppl 11) doi:10.1053/sonc.2001.25437 PubMedCrossRef

54.

Maher EJ (1992) The use of palliative radiotherapy in the management of breast cancer. Eur J Cancer 28(2–3):706–710 doi:10.1016/S0959-8049(05)80131-5 PubMedCrossRef

55.

Marinangeli F, Ciccozzi A, Leonardis M, Aloisio L, Mazzei A, Paladini A et al (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 27(5):409–416 doi:10.1016/j.jpainsymman.2003.10.006 PubMedCrossRef

56.

Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S et al (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12(6):1164–1172PubMed

57.

Markowitz GS, Fine PL, Stack JI, Kunis CL, Radhakrishnan J, Palecki W et al (2003) Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 64(1):281–289 doi:10.1046/j.1523-1755.2003.00071.x PubMedCrossRef

58.

Marx RE, Sawatari Y, Fortin M, Broumand V (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63(11):1567–1575 doi:10.1016/j.joms.x2005.07.010 PubMedCrossRef

59.

McQuay HJ, Collins SL, Carroll D, Moore RA (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev (2):CD001793

60.

Menssen HD, Sakalová A, Fontana A, Herrmann Z, Boewer C, Facon T et al (2002) Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 20(9):2353–2359 doi:10.1200/JCO.2002.02.032 PubMedCrossRef

61.

Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69(1–2):1–18 doi:10.1016/S0304-3959(96)03267-8 PubMedCrossRef

62.

Mercadante S (2006) Scoring the effect of radiotherapy for painful bone metastases. Support Care Cancer 14(9):967–969 doi:10.1007/s00520-006-0036-7 PubMedCrossRef

63.

Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB (2005) Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 136(12):1658–1668PubMed

64.

Nielsen OS, Bentzen SM, Sandberg E, Gadeberg CC, Timothy AR (1998) Randomized trial of single dose versus fractionated palliative radiotherapy of bone metastases. Radiother Oncol 47(3):233–240 doi:10.1016/S0167-8140(98)00011-5 PubMedCrossRef

65.

Nilsson S, Franzén L, Parker C, Tyrrell C, Blom R, Tennvall J et al (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8(7):587–594 doi:10.1016/S1470-2045(07)70147-X PubMedCrossRef

66.

Palma MA, Body JJ (2005) Usefulness of bone formation markers in breast cancer. Int J Biol Markers 20(3):146–155PubMed

67.

Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev (3):CD003474, Jul 20

68.

Pecherstorfer M, Rivkin S, Body JJ, Diel I, Bergström B (2006) Long-term safety of intravenous ibandronic acid for up to 4years in metastatic breast cancer: an open-label trial. Clin Drug Investig 26(6):315–322 doi:10.2165/00044011-200626060-00002 PubMedCrossRef

69.

Perez CA, Brady LW, Halperin EC, Schmidt-Ullrich RK (2004) Principles and practice of radiation oncology, 4th edn. Lippencott, Williams and Wilkins, Philadelphia

70.

Pflugmacher R, Schleicher P, Schroder RJ, Melcher I, Klostermann CK (2006) Maintained pain reduction in five patients with multiple myeloma 12months after treatment of the involved cervical vertebrae with vertebroplasty. Acta Radiol 47(8):823–829 doi:10.1080/02841850600812728 PubMedCrossRef

71.

Pflugmacher R, Beth P, Schroeder RJ, Schaser KD, Melcher I (2007) Balloon kyphoplasty for the treatment of pathological fractures in the thoracic and lumbar spine caused by metastasis: one-year follow-up. Acta Radiol 48(1):89–95 doi:10.1080/02841850601026427 PubMedCrossRef

72.

Ripamonti C, Fulfaro F (2000) Malignant bone pain: pathophysiology and treatments. Curr Rev Pain 4(3):187–196PubMed

73.

Robertson AG, Reed NS, Ralston SH (1995) Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 13(9):2427–2430PubMed

74.

Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350(16):1655–1664 doi:10.1056/NEJMra030831 PubMedCrossRef

75.

Roque M, Martinez MJ, Alonso P, Catala E, Garcia JL, Ferrandiz M (2003) Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev (4):CD003347

76.

Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 100(12):2613-2621PubMedCrossRef

77.

Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M et al (2003) Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 21(16):3150–3157 doi:10.1200/JCO.2003.04.105 PubMedCrossRef

78.

Rosen LS, Gordon D, Kaminski M et al (2007) Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 7:377–387

79.

Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62(5):527–534 doi:10.1016/j.joms.2004.02.004 PubMedCrossRef

80.

Russell RG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9(suppl 2):S66–S80 doi:10.1007/PL00004164 PubMedCrossRef

81.

Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Zoledronic Acid Prostate Cancer Study Group et al (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94(19):1458–1468PubMed

82.

Saad F, Karakiewicz P, Perrotte P (2005) The role of bisphosphonates in hormone-refractory prostate cancer. World J Urol 23(1):14–18 doi:10.1007/s00345-004-0472-2 PubMedCrossRef

83.

Sabino MAC, Mantyh PW (2005) Pathophysiology of bone cancer pain. J Support Oncol 3(1):15–24PubMed

84.

Serafini AN (2001) Therapy of metastatic bone pain. J Nucl Med 42(6):895–906PubMed

85.

Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629–2638 doi:10.2165/00003495-200464230-00002 PubMedCrossRef

86.

Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO (2003) Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol 21(23):4277–4284 doi:10.1200/JCO.2003.05.147 PubMedCrossRef

87.

Strang P, Nilsson S, Brändstedt S, Sehlin J, Borghede G, Varenhorst E, Bandman U, Borck L, Englund G, Selin L (1997) The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res 17(6D):4717–4721PubMed

88.

Strasser F (2005) Promoting science in a pragmatic world: not (yet) time for partial opioid rotation. Support Care Cancer 13(10):765–768 doi:10.1007/s00520-005-0855-y PubMedCrossRef

89.

Sugawara Y, Kajihara M, Semba T, Ochi T, Fujii T, Mochizuki T (2005) Healing focal “flare” phenomenon after radiotherapy in a bone metastasis from bladder cancer. Clin Nucl Med 30(10):672–673 doi:10.1097/01.rlu.0000178028.13072.36 PubMedCrossRef

90.

Sze WM, Shelley M, Held I, Mason M (2004) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy—a systematic review of the randomised trials. Cochrane Database Syst Rev (2):CD004721

91.

Tubiana-Hulin M, Beuzeboc P, Mauriac L, Barbet N, Frenay M, Monnier A et al (2001) Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases (Article in French). Bull Cancer 88(7):701–707PubMed

92.

Vakaet LA, Boterberg T (2004) Pain control by ionizing radiation of bone metastasis. Int J Dev Biol 48(5–6):599–606 doi:10.1387/ijdb.041817lv PubMedCrossRef

93.

Van Poznak CH (2002) The use of bisphosphonates in patients with breast cancer. Cancer Control 9(6):480–489PubMed

94.

Vassiliou K, Kalogeropoulou C, Christopoulos CH, Solomou EK, Kardamakis D (2006) Treating bone metastases from solid tumors with a combination of ibandronate and radiotherapy: clinical evaluation and radiological assessment. Bone 38(3):S85 (suppl 1) abstract 110 doi:10.1016/j.bone.2006.01.056 CrossRef

95.

von Moos R, Cathomas R, Egli F, Inauen R (2006) Loading-dose ibandronate rapidly reduces metastatic bone pain. Ann Oncol 17(suppl 9):78 abstract 928P

96.

Wagner W (2007) Procollagen-I-propeptide and β-crosslaps are prognostic markers for pretherapeutic estimation of treatment success of combined radio- and bisphosphonate therapy in patients with bone metastases—a phase-II study. J Clin Oncol 25(18S):Abstract 9096

97.

Weinfurt KP, Anstrom KJ, Castel LD, Schulman KA, Saad F (2006) Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer. Ann Oncol 17(6):986–989 doi:10.1093/annonc/mdl041 PubMedCrossRef

98.

Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev (2):CD002068

99.

Wu JS, Wong RKS, Lloyd NS, Johnston M, Bezjak A, Whelan T, Supportive Care Guidelines Group of Cancer Care Ontario (2004) Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases—an evidence-based practice guideline. BMC Cancer 4:71 doi:10.1186/1471-2407-4-71 PubMedCrossRef

100.

Yau V, Chow E, Davis L, Holden L, Schueller T, Danjoux C (2004) Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage 27(1):1–3 letter to the editor doi:10.1016/j.jpainsymman.2003.10.003 PubMedCrossRef

101.

Zarychanski R, Elphee E, Walton P, Johnston J (2006) Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 81(1):73–75 doi:10.1002/ajh.20481 PubMedCrossRef

102.

Anonymous (2007) Zoledronic acid (Zometa) [prescribing information]. Novartis Pharmaceuticals Corporation, East Hanover

Title: Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Authors: Roger von Moos
Florian Strasser
Silke Gillessen
Kathrin Zaugg
Publication date: 01-10-2008
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 10/2008
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-008-0487-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Mechanisms of bone pain

Treatment options for bone pain

Please log in to get access to this content

Other articles of this Issue 10/2008

What do we know about fatigue?

Impact of skeletal complications on patients’ quality of life, mobility, and functional independence

Established and potential therapeutic applications of octreotide in palliative care

Meaning in life assessed with the “Schedule for Meaning in Life Evaluation” (SMiLE): a comparison between a cancer patient and student sample

A study of work changes due to cancer in tumor-free primary-treated cancer patients. A NOCWO study

Fatigue in patients with advanced cancer: a pilot study of an intervention with infliximab

Keynote webinar | Spotlight on antibody–drug conjugates in cancer